<ul data-eligibleForWebStory="false"><li>India's Glenmark Pharmaceuticals signed an exclusive licensing agreement with AbbVie for its drug candidate ISB 2001, receiving a $700 million upfront payment.</li><li>IGI's drug candidate has shown promise in treating patients with relapsed/refractory multiple myeloma, leading to a significant deal with AbbVie.</li><li>Glenmark/IGI is set to receive up to $1.225 billion in milestone payments and royalties, propelling Indian companies to focus on innovation and global standards.</li><li>The success story highlights the importance of deep research, global collaboration, and industry support in propelling Indian pharma into the global research arena.</li></ul>

Editorial. Pharma frontier

Discover more